id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2005-D-0460-0005,FDA,FDA-2005-D-0460,Pediatric Drug Development: Regulatory Considerations—Complying With the Pediatric Research Equity Act and Qualifying for Pediatric Exclusivity Under the Best Pharmaceuticals for Children Act; Draft Guidance for Industry; Availability,Notice,Notice of Availability,2023-05-18T04:00:00Z,2023,5,2023-05-18T04:00:00Z,,2023-05-19T11:42:41Z,2023-10610,0,0,0900006485a1c56a
FDA-2005-D-0460-0008,FDA,FDA-2005-D-0460,"Pediatric Drug Development Under the Pediatric Research Equity Act and the Best Pharmaceuticals for Children Act: Scientific Considerations
Guidance for Industry",Other,Guidance,2023-05-18T04:00:00Z,2023,5,2023-05-18T04:00:00Z,2023-07-18T03:59:59Z,2024-11-07T01:34:35Z,,1,0,0900006485a1d33b
FDA-2005-D-0460-0007,FDA,FDA-2005-D-0460,"Pediatric Drug Development: Regulatory Considerations — Complying With the
Pediatric Research Equity Act and Qualifying for Pediatric Exclusivity Under
the Best Pharmaceuticals for Children Act Guidance for Industry",Other,Guidance,2023-05-18T04:00:00Z,2023,5,2023-05-18T04:00:00Z,2023-07-18T03:59:59Z,2026-01-10T12:32:26Z,,1,0,0900006485a1cc08
FDA-2005-D-0460-0006,FDA,FDA-2005-D-0460,"Pediatric Drug Development Under the Pediatric Research Equity Act and the
Best Pharmaceuticals for Children Act: Scientific Considerations; Draft Guidance for Industry; Availability",Notice,Notice of Data Availability,2023-05-18T04:00:00Z,2023,5,2023-05-18T04:00:00Z,,2023-05-19T11:43:06Z,2023-10611,0,0,0900006485a1c5b1